347 related articles for article (PubMed ID: 27226153)
1. Heart rate reduction in coronary artery disease and heart failure.
Ferrari R; Fox K
Nat Rev Cardiol; 2016 Aug; 13(8):493-501. PubMed ID: 27226153
[TBL] [Abstract][Full Text] [Related]
2. Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial.
Badar AA; Perez-Moreno AC; Hawkins NM; Jhund PS; Brunton AP; Anand IS; McKelvie RS; Komajda M; Zile MR; Carson PE; Gardner RS; Petrie MC; McMurray JJ
Circ Heart Fail; 2015 Jul; 8(4):717-24. PubMed ID: 26067854
[TBL] [Abstract][Full Text] [Related]
3. Advances in the management of heart failure: the role of ivabradine.
Müller-Werdan U; Stöckl G; Werdan K
Vasc Health Risk Manag; 2016; 12():453-470. PubMed ID: 27895488
[TBL] [Abstract][Full Text] [Related]
4. The relationship of lower heart rate to mortality and the benefits of exclusive heart rate reduction in ischaemia.
Cardiovasc J Afr; 2007; 18(5):338-40. PubMed ID: 17985037
[No Abstract] [Full Text] [Related]
5. Decreasing heart rate in heart failure: pros and cons.
Natale E; Marsocci A
J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e96-e98. PubMed ID: 29538153
[No Abstract] [Full Text] [Related]
6. Heart rate in coronary syndromes and heart failure.
Orso F; Baldasseroni S; Maggioni AP
Prog Cardiovasc Dis; 2009; 52(1):38-45. PubMed ID: 19615492
[TBL] [Abstract][Full Text] [Related]
7. Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.
Borer JS; Deedwania PC; Kim JB; Böhm M
Am J Cardiol; 2016 Dec; 118(12):1948-1953. PubMed ID: 27780557
[TBL] [Abstract][Full Text] [Related]
8. Marine omega-3 highly unsaturated fatty acids: From mechanisms to clinical implications in heart failure and arrhythmias.
Glück T; Alter P
Vascul Pharmacol; 2016 Jul; 82():11-9. PubMed ID: 27080538
[TBL] [Abstract][Full Text] [Related]
9. Long-term risk and predictors of cardiovascular death in stable coronary artery disease: the CORONOR study.
Bauters C; Tricot O; Meurice T; Lamblin N;
Coron Artery Dis; 2017 Dec; 28(8):636-641. PubMed ID: 28914638
[TBL] [Abstract][Full Text] [Related]
10. Heart rate distribution and predictors of increased heart rate among French hypertensive patients with stable coronary artery disease. Data from the LHYCORNE cohort.
Lorgis L; Zeller M; Jourdain P; Beaune J; Cambou JP; Vaisse B; Chamontin B; Cottin Y
Arch Cardiovasc Dis; 2009; 102(6-7):541-7. PubMed ID: 19664574
[TBL] [Abstract][Full Text] [Related]
11. Heart rate control in an unselected consecutive population of outpatients with stable coronary artery disease: Analysis of the CARDIf Study Cohort.
Vitale C; Iellamo F; Volterrani M; Lombardi M; Fini M; Banach M; Rosano GM
Angiology; 2010 Nov; 61(8):763-7. PubMed ID: 20462892
[TBL] [Abstract][Full Text] [Related]
12. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
Canet E; Lerebours G; Vilaine JP
Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
[TBL] [Abstract][Full Text] [Related]
13. Is foxglove effective in heart failure?
Chaggar PS; Shaw SM; Williams SG
Cardiovasc Ther; 2015 Aug; 33(4):236-41. PubMed ID: 25925484
[TBL] [Abstract][Full Text] [Related]
14. Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction.
Heusch G; Kleinbongard P
Drugs; 2016 May; 76(7):733-40. PubMed ID: 27041289
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease.
Omland T; Pfeffer MA; Solomon SD; de Lemos JA; Røsjø H; Šaltytė Benth J; Maggioni A; Domanski MJ; Rouleau JL; Sabatine MS; Braunwald E;
J Am Coll Cardiol; 2013 Mar; 61(12):1240-9. PubMed ID: 23414791
[TBL] [Abstract][Full Text] [Related]
16. Relationship of Provider and Practice Volume to Performance Measure Adherence for Coronary Artery Disease, Heart Failure, and Atrial Fibrillation: Results From the National Cardiovascular Data Registry.
Fleming LM; Jones P; Chan PS; Andrei AC; Maddox TM; Farmer SA
Circ Cardiovasc Qual Outcomes; 2016 Jan; 9(1):48-54. PubMed ID: 26646817
[TBL] [Abstract][Full Text] [Related]
17. Heart rate and heart failure: the role of ivabradine therapy.
Reil JC; Böhm M
Curr Opin Cardiol; 2013 May; 28(3):326-31. PubMed ID: 23549235
[TBL] [Abstract][Full Text] [Related]
18. API expert consensus document on management of ischemic heart disease.
Association of Physicians of India
J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
[TBL] [Abstract][Full Text] [Related]
19. Ivabradine in stable coronary artery disease without clinical heart failure.
Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R;
N Engl J Med; 2014 Sep; 371(12):1091-9. PubMed ID: 25176136
[TBL] [Abstract][Full Text] [Related]
20. Burden and Prevention of Adverse Cardiac Events in Patients with Concomitant Chronic Heart Failure and Coronary Artery Disease: A Literature Review.
Lavoie L; Khoury H; Welner S; Briere JB
Cardiovasc Ther; 2016 Jun; 34(3):152-60. PubMed ID: 26915344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
